"DHAT Research Institute, a division of Digestive Health Associates of Texas, brings the future of gastroenterology medicine to Adults and Pediatrics in the Dallas-Fort Worth area. We strive to provide all patients, current and new, with access to cutting edge treatments prior to them being granted FDA approved. For new treatments and therapies to receive FDA approval, the investigational product must pass through four different phases: Phase 1, Phase 2 and Phase 3, are pre-FDA approval, while Phase 4 is considered post-FDA approval. DHAT Research Institute participates in all four Phases, 1 through 4, with our primary focus in Phase 2 and Phase 3 of the clinical research testing phase."

During the past decade, DHAT Research Institute conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "DHAT Research Institute" #1 sponsor was "Celgene" with 3 trials, followed by "Adare Pharmaceuticals, Inc." with 1 trials sponsored, "Gilead Sciences" with 1 trials sponsored, "Mirum Pharmaceuticals, Inc." with 1 trials sponsored and "Takeda" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

According to Clinical.Site data, the most researched conditions in "DHAT Research Institute" are "Crohn Disease" (3 trials), "Colitis, Ulcerative" (1 trials), "Eosinophilic Esophagitis" (1 trials), "Non-Alcoholic Steatohepatitis" (1 trials) and "Nonalcoholic Steatohepatitis" (1 trials). Many other conditions were trialed in "DHAT Research Institute" in a lesser frequency.

Most popular intervention types in "DHAT Research Institute" are "Drug" (7 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Ozanimod" (3 trials), "APT-1011" (1 trials), "Placebo to match SEL 18 mg" (1 trials) and "Placebo to match SEL 6 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "DHAT Research Institute" are 7 trials for "All" genders.

Currently, there are NaN active trials in "DHAT Research Institute". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in DHAT Research Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in DHAT Research Institute, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".